Bicara Therapeutics (BCAX) Current Leases (2023 - 2026)

Bicara Therapeutics has reported Current Leases for 4 years, with the latest figure at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases rose 92.89% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (up 92.89% YoY), and the FY2025 full-year result was $1.1 million, up 84.02% from the prior year.
• Current Leases for Q1 2026 stood at $1.1 million, up from $1.1 million in the prior quarter.
• The five-year high for Current Leases was $1.1 million in Q1 2026, with the low at $285000.0 in Q4 2023.
• Historically, Current Leases has averaged $777125.0 across 4 years, with a median of $840500.0 in 2024.
• The largest YoY upside for Current Leases was 255.52% in 2025 against a maximum downside of 84.02% in 2025.
• Bicara Therapeutics' Current Leases stood at $285000.0 in 2023, then jumped by 112.98% to $607000.0 in 2024, then jumped by 84.02% to $1.1 million in 2025, then increased by 2.06% to $1.1 million in 2026.
• The last three Current Leases figures came in at $1.1 million (Q1 2026), $1.1 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.